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Material and Methods 
 
Neuropathological examination was performed using paraffin-embedded tissue blocks of 
various cortical regions, basal ganglia, thalamus, hippocampus, brainstem and cerebellum 
using standard and published methods and various anti-PrP antibodies.1 The study was 
approved by the Ethical Committee of the Medical University of Vienna (Nr. 396/2011). 
Frozen tissues from selected brain regions from this case were available for biochemical 
analysis. Tissues were analyzed for the presence of protease resistant PrP (PrPres) as 
previously described.2 Selected UK cases of sporadic and variant Creutzfeldt-Jakob disease 
(vCJD) were used as reference standards for the Western blot analysis. They were obtained 
from the CJD Brain and Tissue Bank (part of Edinburgh Brain and Tissue Banks); the use of 
these tissues is covered by ethics approval 11/ES/0022, Edinburgh Brain Bank.   
 
Clinical observations 
 
Based on clinical scales, the change in MMSE was noteworthy (22/30 in September 2007, 
13/30 in January 2008, and 0/30 from August 2008 on; Barthel index was 100/100 in June, 
2007, 95/100 in September, 2007, 60/100 in January, 2008, 30/100 in August, 2008 and 0/100 
in December, 2008). 
 
Diffusion restriction had resolved 3.5 years after baseline imaging  and  a marked atrophy had 
evolved (Suppl. Figure 1A, B) with progression on CT after  4.5 years (Suppl. Figure 1 C, 
D).   
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Suppl. Figure 1. DWI (A, B) and cranial CT (C, D). 
 
A        B 
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Neuropathological observations 
Macroscopic evaluation revealed cortical atrophy and enlargement of the ventricles. A 
moderate degree of spongiform change and gliosis was seen in the frontal, temporal, parietal 
and occipital cortices and nucleus accumbens, while mild or focal spongiform change was 
noted in the striatum, thalamus, hippocampal subregions and cerebellar cortex. Reactive 
gliosis was prominent in the striatum and amygdala. Neurons in the cortical areas, 
hippocampus, and cerebellum were relatively well preserved. In the brainstem the locus 
coeruleus and substantia nigra showed moderate neuronal loss and eosinophilic Lewy bodies 
(Suppl. Figure 2).  
 
Suppl. Figure 2. Lewy bodies (arrows) in the substantia nigra (Bar: 25 µm). 
 
 
Immunostaining for PrP showed a diffuse synaptic pattern with loose clusters of granular 
deposits in the cortex and small droplets (8-12 µm) in the white matter (Suppl. Figure 3). 
These did not resemble the dystrophic neurites that are immunostained for PrPC in the cortex 
in Alzheimer disease samples. 
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Suppl. Figure 3. PrP immunoreactive droplets in the parietal white matter (bar: 25 µm). 
  
Intraneuronal dots and somatosynaptic type of PrP immunoreactivity were noted in the 
anterior horn motor neurons of the cervical spinal cord (Suppl. Figure 4 A, B). This 
corresponds to the somato-synaptic and intraneuronal fine dot-like pattern seen mostly in VV 
and MV type 2 sporadic CJD cases mostly in the brainstem/thalamus (Suppl. Figure 4 C). 
 
Suppl. Figure 4. PrP immunoreactivity in the lower motor neurons (cervical spinal cord). 
A and B is the present case, C is a sporadic CJD VV type 2 case used as control (pons base 
shown here). Bar in B: 25 µm. 
A            B                 C 
 
 
In the thalamus and cerebellar cortex mostly the granular- and microplaque-like PrP 
immunoreactivity was seen (Suppl. Figure 5 A-H). Microplaques were not seen 
unequivocally in adjacent section stained for Haematoxylin and eosin. 
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Suppl. Figure 5. PrP immunoreactivity in the thalamus (A) and cerebellum (C, E, G) shows 
microplaque-like immunoreactivity. However, these are not detected unequivocally in the 
Haematoxylin and Eosin stainined sections of the thalamus (B) and cerebellum (D, F, H). Bar 
in A represents 50 µm for A, B and E-H and 150 µm for C and D.  
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The most prominent degree of PrP immunoreactivity was seen in the parietal and occipital 
cortices, thalamus and cerebellum. Comparison of different anti-PrP antibodies revealed that 
3F4 (Suppl. Figure 6A), KG9, L42 and 12F10 (Suppl. Figure 6B) were the most effective to 
detect the immunoreactivites, while 6H4 (Suppl. Figure 6C) showed only weak results.  
 
Suppl. Figure 6. Comparison of PrP immunoreactivity in the cerebellum as visualized by 
antibody 3F4 (J), 12F10 (K) and 6H4 (L). Bar in C represents 50 µm. 
A        B          C 
 
 
Immunostaining for phospho-tau (AT8) revealed small neuritic profiles (Suppl. Figure 7) as 
seen also in sporadic CJD brains.  
 
Suppl. Figure 7. Phospho-tau (AT8) immunoreactivity in the frontal cortex (bar: 25 µm). 
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Comments  
 
The neuropathological features together with the Western blot profile of this case, including 
poorly protease-resistant PrP, an approximately 8kDa band, and additional 19kDa and 23kDa 
bands in the cerebellum, are consistent with VPSPr.2-4 Moreover the PRNP codon 129 
genotype of the patient (VV) is the one in which VPSPr most commonly occurs.3, 4 
 
In the striatum mostly gliosis was observed, while in the neocortex gliosis and spongiform 
alterations were noted. The severity of these histopathological features overlapped with the 
areas in DWI showing high signal and also with the atrophy seen in the CT. 
 
Interestingly, pentosan-polysulphate therapy in vCJD seems to be associated with prolonged 
survival, but prominent tissue damage of the brain.5 In vitro and in vivo studies have shown 
that doxycycline renders PrPSc protease sensitive, reduces the infectivity titer in prion-
contaminated material, and prolongs the survival of experimentally prion-infected animals, 
but had no apparent effect on disease characteristics or duration in a randomized, double-blind 
placebo-contolled trial in patients with sporadic and genetic forms of CJD.6  
Detection of VPSPr in a cognitively normal 93-year-old individual suggests that PrP 
production in VPSPr might in itself be less neurotoxic.7  
Of note, restricted diffusion was widespread in the baseline imaging of the basal ganglia and 
cerebral cortex, but declined over the years. We are not aware of any characteristic MRI 
feature of VPSPr but it is of note that the first MRI images were similar to that seen in 
sporadic CJD. 
Lewy body pathology 8 as well as lack of microplaques detectable in H&E 2 has been also 
reported in VPSPr. Neuronal loss in the pigmented brainstem nuclei correlated with the 
presence of Lewy bodies. 
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